Literature DB >> 33023915

Assessment of and Interventions for Women at High Risk for Breast or Ovarian Cancer: A Survey of Primary Care Physicians.

Goli Samimi1, Brandy M Heckman-Stoddard2, Christine Holmberg3, Bethany Tennant4, Bonny Bloodgood Sheppard4, Kisha I Coa4, Shelley S Kay4, Leslie G Ford2, Eva Szabo2, Lori M Minasian2.   

Abstract

As clinical guidelines for cancer prevention refer individuals to primary care physicians (PCP) for risk assessment and clinical management, PCPs may be expected to play an increasing role in cancer prevention. It is crucial that PCPs are adequately supported to assess an individual's cancer risk and make appropriate recommendations. The objective of this study is to assess use, familiarity, attitude, and behaviors of PCPs regarding breast and ovarian cancer risk and prevention, to better understand the factors that influence their prescribing behaviors. We conducted a cross-sectional, web-based survey of PCPs in the United States, recruited from an opt-in healthcare provider panel. Invitations were sent in batches until the target sample size of 750 respondents (250 each for obstetrics/gynecology, internal medicine, and family medicine) was met. Self-reported use of breast/ovarian cancer risk assessments was low (34.7%-59.2%) compared with discussion of cancer family history (96.9%), breast exams (87.1%), and mammograms (92.8%). Although most respondents (48.0%-66.8%) were familiar with cancer prevention interventions, respondents who reported to be less familiar were more likely to report cautious attitudes. When presented with hypothetical cases depicting patients at different breast/ovarian cancer risks, up to 34.0% of respondents did not select any of the clinically recommended course(s) of action. This survey suggests that PCP use of breast/ovarian cancer risk assessment tools and ability to translate the perceived risks to clinical actions is variable. Improving implementation of cancer risk assessment and clinical management guidelines within primary care may be necessary to improve the appropriate prescribing of cancer prevention interventions.Prevention Relevance: Primary care physicians are becoming more involved in cancer prevention management, so it is important that cancer risk assessment and medical society guideline recommendations for cancer prevention are better integrated into primary care to improve appropriate prescribing of cancer prevention interventions and help reduce cancer risk. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2020        PMID: 33023915      PMCID: PMC8021601          DOI: 10.1158/1940-6207.CAPR-20-0407

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  45 in total

1.  The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention.

Authors:  Peter M Ravdin
Journal:  Cancer Prev Res (Phila)       Date:  2010-06

2.  Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

Authors:  Douglas K Owens; Karina W Davidson; Alex H Krist; Michael J Barry; Michael Cabana; Aaron B Caughey; Chyke A Doubeni; John W Epling; Martha Kubik; C Seth Landefeld; Carol M Mangione; Lori Pbert; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng; John B Wong
Journal:  JAMA       Date:  2019-08-20       Impact factor: 56.272

Review 3.  Barriers to the Use of Breast Cancer Risk Reduction Therapies.

Authors:  Arvind Bambhroliya; Mariana Chavez-MacGregor; Abenaa M Brewster
Journal:  J Natl Compr Canc Netw       Date:  2015-07       Impact factor: 11.908

4.  Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  Cancer Prev Res (Phila)       Date:  2010-04-19

5.  Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement.

Authors:  David C Grossman; Susan J Curry; Douglas K Owens; Michael J Barry; Karina W Davidson; Chyke A Doubeni; John W Epling; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Carol M Mangione; Maureen G Phipps; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng
Journal:  JAMA       Date:  2018-02-13       Impact factor: 56.272

6.  Cancer Prevention in Primary Care: Perception of Importance, Recognition of Risk Factors and Prescribing Behaviors.

Authors:  Goli Samimi; Brandy M Heckman-Stoddard; Christine Holmberg; Bethany Tennant; Bonny Bloodgood Sheppard; Kisha I Coa; Shelley S Kay; Leslie G Ford; Eva Szabo; Lori M Minasian
Journal:  Am J Med       Date:  2019-12-17       Impact factor: 4.965

7.  Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.

Authors:  Panagiotis A Konstantinopoulos; Barbara Norquist; Christina Lacchetti; Deborah Armstrong; Rachel N Grisham; Paul J Goodfellow; Elise C Kohn; Douglas A Levine; Joyce F Liu; Karen H Lu; Dorinda Sparacio; Christina M Annunziata
Journal:  J Clin Oncol       Date:  2020-01-27       Impact factor: 44.544

8.  Chemoprevention for Breast Cancer.

Authors:  Sandhya Pruthi; Ruth E Heisey; Therese B Bevers
Journal:  Ann Surg Oncol       Date:  2015-07-23       Impact factor: 5.344

9.  Risk-reducing mastectomy rates in the US: a closer examination of the Angelina Jolie effect.

Authors:  Alexander Liede; Mona Cai; Tamara Fidler Crouter; Daniela Niepel; Fiona Callaghan; D Gareth Evans
Journal:  Breast Cancer Res Treat       Date:  2018-05-28       Impact factor: 4.872

10.  Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care.

Authors:  Thomas B Silverman; Alejandro Vanegas; Awilda Marte; Jennie Mata; Margaret Sin; Juan Carlos Rodriguez Ramirez; Wei-Yann Tsai; Katherine D Crew; Rita Kukafka
Journal:  BMC Health Serv Res       Date:  2018-08-13       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.